Wire · opportunities
Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 September 2026 · Fusion42 review
The FDA has granted final approval to Handa Oncology's OMCAZIO (cabozantinib) capsules for multiple cancer indications, allowing commercialisation in the U.S. OMCAZIO's ability to be taken with or without food offers patients more flexible treatment options.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 11 Sep 2026 and 12 Sep 2026.
◆ ◆ The Wire takeaway
Your cancer drug development must adjust to OFCAZIO’s approved flexibility with food, as this approval unlocks a competitive edge in patient convenience over incumbent treatments. Manufacturers and distributors now face a tighter race to meet newly flexible dosing demands in U.S. oncology markets.
◆ Coverage
2 sources · first reported 11 Sep 2026 · latest 12 Sep 2026
◆ Related on Wire
◆ Topics